Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CCH Injection Techniques for Cellulite (EFP)
NCT03632993Phase 2Completed
- Sponsor
- Endo International plc
- Start
- Sep 2018
- Primary completion
- Jan 2019
- Modality
- Therapeutic Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of collagenase clostridium histolyticum in cellulite (5 arms), sponsored by Endo International plc. Primary endpoints: Aesthetic Appearance Improvement Likert Scores at Day 71 and Change From Baseline in Dimple Depth Depression (Hexsel CSS [B]) at Day 71. Started Sep 2018; status: completed.
02
Drugs
collagenase clostridium histolyticum
03
Conditions
cellulite
Beyond the preview
Go deeper on NCT03632993.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03632993.